A Pfeifferet al Gut 36813818 1995
62. M P. Caulfield and N. J. Birdsall, Pharmacol. Rev., 50,279-290 1998 . 63. A. Pfeiffereet al, Dig. Dis. Sci., 35,1468-1472 1990 . 64. M. Kajimura, M. A. Reuben, and G. Sachs, Gastroenterology, 103,870-875 1992 . 65. R. M. Wallis and C. M. Napier, Life Sci, 64, 395-401 1999 . 66. H. G. Dammann, M. Dreyer, N. Wolf, P. M ller, B. Merk-H rtelt, and B. Simon, Z. Gastroenterol, 27,203-206 1989 . 67. M. Lazzaroni, O. Sangaletti, F. Parente, B. P. Imbimbo, and G. Bianchi Porro, Znt. J. Clin....
Ulcer Disease
Peptic ulcers arise because of an imbalance of acid-secretory mechanisms and mucosal-pro-tective factors, and the rationale for their treatment is aimed at restoring that balance. The loss of balance between acid secretion and mucosal-protective factors varies among peptic ulcer types. In type I ulcers, which occur high in the stomach, acid hypersecretion is not necessarily evident, suggesting the importance of impaired mucosal-protective factors in this clinical setting. Type II ulcers, in...
HKATPase PROTON PUMP INHIBITION
The enzyme H K -ATPase, or proton pump, regulates the final stage in the cellular cascade that terminates in the secretion of gastric acid. Acid secretion is dependent on the cellular location of the enzyme and the close proximity of a potassium chloride efflux pathway. When the parietal cell transforms from a resting to a stimulated state, cytoskeletal rearrangement occurs and H K -ATPase relocates to the apical plasma membrane. Potassium and chloride ions move across the apical cell membrane...
Info Icv
107. A. Kohn, B. Annibale, G. Delle Fave, and S. Levenstein, Dig. Dis., 11,228-238 1993 . 108. D. G. Colin-Jones, Aliment. Pharmacol. Ther., 9, 9-14 1995 . 109. A. K. Sandvik, E. Brenna, and H. L. Waldum, Aliment. Pharmacol. Ther., 11, 1013-1018 110. A. L. Ganser and J. G. Forte, Biochim. Bio-phys. Acta, 307, 169-180 1973 . 111. G. Sachs, et al., Ann. N. Y. Acad. Sei., 358, 118-137 1980 . 112. S. E. Sjostrand, B. Ryberg, and L. Olbe, Acta Physiol. Scand. special suppl. 1978 . 113. P. Zhang, C....
Info Gnf
channels, thus depolarizing the cell. The change in membrane potential results in the opening of voltage-gated Ca2 channels and an increase in intracellular Ca2 , which triggers insulin release. Sulfonylureas, by block-ingpotassium current through the KATP channel, produce the same effect. The Katp channel is composed of two protein subunits in a ratio of 4 4. One subunit, termed Kir6.2, is a member of the inward rectifying potassium channel family. The other regulatory subunit, SURl, belongs...
O
Aromatic or Heterocyclic Tail with ortho Substituent E Aromatic or Heterocyclic Tail with ortho Substituent E Figure 1.2. Common structural features found in sulfonylurea, benzoic acid, and phenylalanine derived hypoglycemic agents. Figure 1.2. Common structural features found in sulfonylurea, benzoic acid, and phenylalanine derived hypoglycemic agents. stituent is often an N-propyl or N-butyl group, whereas cycloalkyl groups are most common in later compounds. The pendant lipophilic group...
Truncated PTH Analogs Identification of the Minimum Sequence Requirements
Truncation of peptide hormones having more than 15 amino acid residues to smaller yet biologically active and potent analogs is very often a challenging task. Most often truncation not only allows researchers the flexibility cf synthesizing large numbers of analogs with considerable ease, speed, and at less cost, but the truncated analogs also can be studied more systematically to elucidate the regions within the native peptide sequence that are important for binding and bioactivity. SAE...
Reversible ProtonPump Inhibitors
The effectiveness of clinically available PPIs relies on the number of active pumps at any one time and the recovery of pumps after biosynthesis. The prolonged suppression of gastric acid secretion produced by both H2-recep-tor antagonists and PPIs produces extended periods of hypergastrinemia, which has been associated with the formation of precancerous changes in human gastric mucosa and gastric in long-term animal studies. In fact, the development of omeprazole, a protonpump inhibitor, was...
C1
Tabl e 1.4 Structures and Properties of Insulinotropic Agents Glinides Trade Name Manufacturer Chemical Class Starlix . Novartis Phenylalanine channels, but have rapid onset after oral administration and short duration of action. Re-paglinide is the more potent of the two, but nateglinide reportedly has somewhat faster onset and shorter duration of action 81 . 2.2.1 Side Effects, Adverse Effects. Sulfonyl- ureas are generally well tolerated. The major safety concern is severe hypoglycemia, with...
O Iqo
of drug, was found to reduce hyperglycemia, hyperlipidemia, and hypertriglyceridemia in insulin-resistant animal models, but not in normoglycemic animals 181, 182 . Ciglitazone was taken into human trials in NIDDM subjects, but was withdrawn because of low potency and the appearance of cataracts in animals receiving long-term exposure to the drug. It was replaced in development with the more potent pioglitazone 183 , which has subsequently received marketing approval in the United States and...
Structure of the Proton Pump
The H K -ATPase enzyme, present in tubu-lovesicular and canalicular membranes of the gastric parietal cell, consists of two subunits, a 114-kDa a-subunit and a 34-kDa j3-subunit. The a-subunit has been shown to contain 10 transmembrane helices, with the j3-subunit possessing only a single transmembrane helix 113 . The a-subunit carries out the catalytic and transport functions of the enzyme because it contains both ATP and cation binding sites it also contains the sequences responsible for...
Structure and SAR of the ProtonPump Inhibitors
In 1973 workers at AB Haessle in Sweden, identified timoprazole 118 as one of the first well-defined inhibitors of the newly discovered gastric proton pump. This compound stemmed from efforts to separate the toxicity and acid-inhibitory properties of 2-pyridyl-thioacteamide CMN131 . Removal of the thioamide group was considered to be the most likely solution to the toxicity of CMN131, which prompted the preparation of sulfur-containing heterocycles, as well as imidazo-line- and...
Insulin and Hypoglycemic Agents
Mark Sleevi Insmed Incorporated Richmond, Virginia 2 Current Drugs on the Market, 4 2.1.1 Side Effects, Adverse Effects, 5 Absorption, Distribution, Metabolism, and Elimination, 5 2.1.3 Physiology and Pharmacology, 8 2.2.1 Side Effects, Adverse Effects, 15 2.2.2 Absorption, Distribution, Metabolism, and Elimination, 15 2.2.3 Physiology and Pharmacology, 17 2.3 Insulin-Sensitizing Agents, 20 2.3.1.1 Side Effects, Adverse Effects, 21 2.3.1.2 Absorption, Distribution, Metabolism, and Elimination,...
References 1
1. R. Hirschmann, Angew. Chem. Znt Ed. Engl., S0, 1278 1991 . 2. R. Schwyzer, Ann. N. Y. Acad. Sei., 297, 1977 . 3. V.J. Hruby, Life Sei., 31, 189 1982 . 4. H. Kessler, Angew. Chem. Znt Ed. Engl., 2l 512 1982 . 5. R. M. Freidinger and D. F. Veber, Conforma-tionally Directed Drug Design, Vol. 251, American Chemical Society, Washington, DC, 1984, p. 169. 6. V.J. Hruby and M. E. Hadley, Design and Synthesis of Organic Molecules Based on Molecular Recognition, Springer- Verlag, Heidelberg, Germany,...
Hormones and Neurotransmitters Regulating the Secretion of Gastric Acid
The acid-secretingoxyntic cell, or parietal cell, I is the main cell type in the gastric gland. Chief , cells pepsinogen-secretingcells , mucus cells, s and D-cells somatostatin-secreting cells are also found within gastric glands. Somatostatin, released from fundic D-cells, inhibits the release of acid secretion from the parietal cell. These specialized cells are in close proximity to parasympathic nerve endings and neural inputs are able to regulate hormone release 10 .The release of HA from...
Things To Come In Peptide And Peptidomimetic Design
The determination of the genome of humans and many other animals and living systems has opened up enormous opportunities for and peptidomimetic design, and for the development of peptides and peptidomi-metics as drugs, therapeutics, and diagnostic reagents. Most cellular processes and system activities, including those involving diseases, are controlled or modulated by peptide-pro-tein and or protein-protein interactions. In many protein-protein interactions fairly small structural regions of...
TEST ASSAYS FOR STUDYING i GASTRIC ACID INHIBITORS
Gastric acid secretion occurs through receptor-mediated or enzyme-mediated processes. Drug dissociation constants can be determined from in vitro bioassays, allowing affinity estimate comparisons to be made between compounds. Functional evaluation can be made using both in vitro and in vivo techniques, with the latter models being able to provide information on the pharmacokinetics of drug candidates. Technological progress made since the discovery of both H2-receptor antagonists and PPIs means...
Contents
1 INSULIN AND HYPOGLYCEMIC AGENTS, 1 Mark Sleevi Insmed Incorporated Richmond, Virginia 2 PEPTIDE AND PROTEIN HORMONES, PEPTIDE NEUROTRANSMITTERS, AND THERAPEUTIC AGENTS, 45 Victor J. Hruby Catherine Gehrig de Chavez Malcolm Kavarana University of Arizona Department of Chemistry Tucson, Arizona 3 INHIBITORS OF GASTRIC ACID SECRETION, 85 James Black Foundation London, United Kingdom 4 CHEMOKINE AND CYTOKINE MODULATORS, 129 Maria Elena Fuentes Tara Mirzadegan Robert S. Wilhelm 5 COX-2 INHIBITORS...